Filing Flows › Comparisons › CORT vs PBH
Corcept Therapeutics vs Prestige Consumer Healthcare: CORT and PBH compared
Corcept Therapeutics is the larger company: $340M of revenue in its latest quarter (Q3 2026) against $336M for Prestige Consumer Healthcare (Q2 FY27). Corcept Therapeutics is growing faster (+64% against +23% a year earlier). Corcept Therapeutics is more profitable, with an operating margin of 33.7% against 24.0%.
Where the money goes: CORT and PBH
Corcept Therapeutics (CORT) · Q3 2026
Corcept Therapeutics, Q3 2026: revenue $340M (+64% year over year), operating margin 33.7%, net earnings $127M, operating cash flow $143M. The chart follows the revenue to costs, profit and cash.
Prestige Consumer Healthcare (PBH) · Q2 FY27
Prestige Consumer Healthcare, Q2 FY27: revenue $336M (+23% year over year), operating margin 24.0%, net earnings $25.3M, operating cash flow $37.9M. The chart follows the revenue to costs, profit and cash.
| Corcept Therapeutics (CORT) | Prestige Consumer Healthcare (PBH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 FY27 |
| Revenue | $340M | $336M |
| Revenue growth, Y/Y | +64% | +23% |
| Gross margin | — | 51.3% |
| Operating margin | 33.7% | 24.0% |
| Net earnings | $127M | $25.3M |
| Net margin | 37.2% | 7.5% |
| Operating cash flow | $143M | $37.9M |
| Free cash flow | $142M | $34.2M |
| Market value | $9.0B | $2.3B |
| P/E | 57.3× | 13.6× |
| Analysts’ mean target | $142.60 | $66.60 |
Where the revenue comes from
Corcept Therapeutics
- Hypercortisolism Products: $249M (73%)
- Lifyorli: $91.4M (27%)
Prestige Consumer Healthcare
- Gastrointestinal: $63.1M (19%)
- Women's Health: $53.6M (16%)
- Wellness, Sleep & Other: $47.3M (14%)
- Dermatologicals: $43.9M (13%)
Questions
Which is bigger, Corcept Therapeutics or Prestige Consumer Healthcare?
Corcept Therapeutics is the larger company: $340M of revenue in its latest quarter (Q3 2026) against $336M for Prestige Consumer Healthcare (Q2 FY27).
Is Corcept Therapeutics or Prestige Consumer Healthcare growing faster?
Corcept Therapeutics is growing faster (+64% against +23% a year earlier).
Which is more profitable, Corcept Therapeutics or Prestige Consumer Healthcare?
Corcept Therapeutics is more profitable, with an operating margin of 33.7% against 24.0%.
More: Corcept Therapeutics earnings · how Corcept Therapeutics makes money · Prestige Consumer Healthcare earnings · how Prestige Consumer Healthcare makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.